Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Similar articles for PubMed (Select 22923450)

1.

Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.

Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, Zhang Z, Boreddy PR, Wang W, Wang Z, Abbruscato T, Chen Z, Olson JJ, Zhang R, Goodman MM, Nicolaou KC, Van Meir EG.

Clin Cancer Res. 2012 Dec 15;18(24):6623-33. doi: 10.1158/1078-0432.CCR-12-0861. Epub 2012 Aug 24.

2.

Menadione and ethacrynic acid inhibit the hypoxia-inducible factor (HIF) pathway by disrupting HIF-1α interaction with p300.

Na YR, Han KC, Park H, Yang EG.

Biochem Biophys Res Commun. 2013 May 17;434(4):879-84. doi: 10.1016/j.bbrc.2013.04.044. Epub 2013 Apr 22.

PMID:
23618863
3.

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.

Reece KM, Richardson ED, Cook KM, Campbell TJ, Pisle ST, Holly AJ, Venzon DJ, Liewehr DJ, Chau CH, Price DK, Figg WD.

Mol Cancer. 2014 Apr 28;13:91. doi: 10.1186/1476-4598-13-91.

4.

KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R.

PLoS One. 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13.

5.

RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.

Gillespie DL, Aguirre MT, Ravichandran S, Leishman LL, Berrondo C, Gamboa JT, Wang L, King R, Wang X, Tan M, Malamas A, Lu ZR, Jensen RL.

J Neurosurg. 2015 Feb;122(2):331-41. doi: 10.3171/2014.10.JNS132363. Epub 2014 Nov 28.

PMID:
25423275
6.

Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.

Mooring SR, Jin H, Devi NS, Jabbar AA, Kaluz S, Liu Y, Van Meir EG, Wang B.

J Med Chem. 2011 Dec 22;54(24):8471-89. doi: 10.1021/jm201018g. Epub 2011 Nov 23.

7.

Suppressing the malignant phenotypes of glioma cells by lentiviral delivery of small hairpin RNA targeting hypoxia-inducible factor-1α.

Dong CG, Wu WK, Feng SY, Yu J, Shao JF, He GM.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2323-32. eCollection 2013.

8.

Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.

Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E.

Biochem Pharmacol. 2007 Jul 15;74(2):191-201. Epub 2007 Apr 6.

PMID:
17498666
9.

Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.

Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):15-27. doi: 10.1038/pcan.2011.51. Epub 2011 Nov 15.

PMID:
22083267
10.

Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.

Paradziej-Łukowicz J, Skwarska A, Peszyńska-Sularz G, Brillowska-Dąbrowska A, Konopa J.

Cancer Biol Ther. 2011 Oct 1;12(7):586-97. Epub 2011 Oct 1.

11.

Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.

Mun J, Jabbar AA, Devi NS, Yin S, Wang Y, Tan C, Culver D, Snyder JP, Van Meir EG, Goodman MM.

J Med Chem. 2012 Aug 9;55(15):6738-50. doi: 10.1021/jm300752n. Epub 2012 Jul 24.

13.

Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α.

Ma J, Zi Jiang Y, Shi H, Mi C, Li J, Xing Nan J, Wu X, Joon Lee J, Jin X.

Eur J Pharmacol. 2014 Jan 15;723:46-54. doi: 10.1016/j.ejphar.2013.12.005. Epub 2013 Dec 12.

PMID:
24333213
14.

BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I.

Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, Ehrmann A, Summer H, Flamme I, Oehme F, Thierauch K, Michels M, Hess-Stumpp H, Ziegelbauer K.

Cancer Med. 2013 Oct;2(5):611-24. doi: 10.1002/cam4.112. Epub 2013 Aug 20.

15.

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.

Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, Mehlig M, Wang M, Ponzoni M, Greenberger LM, Horak ID.

Angiogenesis. 2011 Sep;14(3):245-53. doi: 10.1007/s10456-011-9209-1. Epub 2011 Mar 31.

16.

Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1α.

Nepal M, Choi HJ, Choi BY, Kim SL, Ryu JH, Kim do H, Lee YH, Soh Y.

Eur J Pharmacol. 2012 Sep 15;691(1-3):28-37. doi: 10.1016/j.ejphar.2012.06.028. Epub 2012 Jul 1.

PMID:
22760073
17.

Visualization of hypoxia-inducible factor 1α-p300 interactions in live cells by fluorescence resonance energy transfer.

Kim SY, Lee MJ, Na YR, Kim SY, Yang EG.

J Cell Biochem. 2014 Feb;115(2):271-80. doi: 10.1002/jcb.24659.

PMID:
23966271
18.

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.

Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G.

Mol Cancer Ther. 2009 Jul;8(7):1867-77. doi: 10.1158/1535-7163.MCT-09-0274. Epub 2009 Jul 7.

19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk